Header Logo

Connection

RAYNE ROUCE to Immunotherapy, Adoptive

Back to Details
This is a "connection" page, showing publications RAYNE ROUCE has written about Immunotherapy, Adoptive.
RAYNE ROUCE
Connection Strength
3.647
Immunotherapy, Adoptive
  1. Access offsets poverty in quest for CAR T cells. Blood. 2023 02 09; 141(6):558-560.
    View in: PubMed
    Score: 0.489
  2. Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):487-493.
    View in: PubMed
    Score: 0.420
  3. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
    View in: PubMed
    Score: 0.147
  4. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
    View in: PubMed
    Score: 0.147
  5. How I Approach Ethical Considerations for Pediatric Phase I CAR T-Cell Trials. Pediatr Blood Cancer. 2025 Aug; 72(8):e31802.
    View in: PubMed
    Score: 0.143
  6. New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. Lancet Oncol. 2025 Apr; 26(4):e214-e224.
    View in: PubMed
    Score: 0.142
  7. Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
    View in: PubMed
    Score: 0.140
  8. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 07 09; 8(13):3544-3548.
    View in: PubMed
    Score: 0.135
  9. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 08; 30(8):776-787.
    View in: PubMed
    Score: 0.133
  10. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.133
  11. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther. 2024 06; 30(6):565-579.
    View in: PubMed
    Score: 0.132
  12. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.132
  13. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132.
    View in: PubMed
    Score: 0.128
  14. Bringing CAR T?cell therapy trials to underserved populations. Cancer Cell. 2023 12 11; 41(12):2007-2010.
    View in: PubMed
    Score: 0.128
  15. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 03; 29(3):165.e1-165.e7.
    View in: PubMed
    Score: 0.121
  16. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 11 10; 4(21):5414-5424.
    View in: PubMed
    Score: 0.105
  17. Replacing CAR-T cell resistance with persistence by changing a single residue. J Clin Invest. 2020 06 01; 130(6):2806-2808.
    View in: PubMed
    Score: 0.101
  18. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.097
  19. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
    View in: PubMed
    Score: 0.090
  20. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.090
  21. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.083
  22. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
    View in: PubMed
    Score: 0.083
  23. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
    View in: PubMed
    Score: 0.082
  24. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704.
    View in: PubMed
    Score: 0.080
  25. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
    View in: PubMed
    Score: 0.072
  26. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
    View in: PubMed
    Score: 0.034
  27. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760.
    View in: PubMed
    Score: 0.031
  28. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.